Potential Dementia Prevention: Impact of Diabetes Drug Explored

A recent study on the Korean population suggests that SGLT-2 inhibitor drugs, used to treat type 2 diabetes, could reduce the risk of dementia by up to 48% when used for over two years. The study calls for randomized controlled trials to confirm these observational findings.

A recent study has suggested that a common diabetes drug might prevent dementia, offering more benefits with longer treatment durations. Conducted on over 200,000 Korean adults aged between 40 and 69 years with type 2 diabetes, the researchers discovered a 35% reduced risk of dementia in those taking SGLT-2 inhibitors compared to DPP-4 inhibitors.

Notably, extending the treatment with SGLT-2 drugs resulted in even better outcomes, with a 48% reduced risk of dementia observed in patients treated for more than two years. Despite these promising results, the researchers from the Seoul National University Bundang Hospital advise that randomized controlled trials (RCTs) are necessary to validate the findings.

Paul Parkinson's Disorder Treatment Methods, differences in participant health behaviors, such as smoking and alcohol consumption, and the duration for which they had type 2 diabetes were factors not fully accounted for, making the need for more rigorous trials evident. However, the large scale and the nationally representative nature of the study lend significant weight to the results.

(With inputs from agencies.)